Global Canine Atopic Dermatitis Market By Product (Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs) and Others), By Type (Prescription and OTC), By Dog Breed (Retrievers, German Shepherds, Terriers and Others), By Mode of Administration (Oral, Topical and Injectable), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Report Overview

The Global Canine Atopic Dermatitis Market size is expected to be worth around US$ 16.3 Billion by 2035 from US$ 5.7 Billion in 2025, growing at a CAGR of 11.1% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 41.2% share with a revenue of US$ 2.4 Billion.

Increasing prevalence of allergic skin conditions in companion animals propels the Canine Atopic Dermatitis market as pet owners and veterinarians demand effective, long-term therapies that alleviate pruritus, reduce inflammation, and improve quality of life for affected dogs.

Veterinarians increasingly prescribe Janus kinase inhibitors such as oclacitinib to rapidly control acute flare-ups of atopic dermatitis, blocking cytokine signaling pathways that drive itch and skin lesions in dogs with environmental or food allergen sensitivities. These treatments support chronic management by reducing the frequency and severity of relapses in patients with perennial or seasonal allergies.

Monoclonal antibodies targeting interleukin-31 provide targeted relief from pruritus, interrupting the itch-scratch cycle and allowing skin barrier repair in dogs refractory to conventional therapies. Clinicians combine these systemic agents with topical corticosteroids or calcineurin inhibitors for localized lesions on the paws, ventral abdomen, or axillae, minimizing systemic exposure while addressing focal dermatitis.

Supportive therapies, including hypoallergenic diets and allergen-specific immunotherapy, complement pharmacologic options by addressing underlying triggers and promoting sustained remission in dogs with confirmed environmental sensitivities.

Pharmaceutical companies pursue opportunities to develop novel biologics and small-molecule inhibitors with extended dosing intervals, expanding applications in long-term maintenance for dogs with severe, recurrent atopic dermatitis. These advancements support combination regimens that integrate antipruritic agents with barrier-repair topicals and microbiome-modulating shampoos, enhancing overall skin health and reducing reliance on broad-spectrum antimicrobials.

Opportunities emerge in personalized treatment protocols guided by biomarker profiling and allergen testing, optimizing outcomes in dogs with complex allergic phenotypes. Companies invest in chewable and injectable formats that improve owner compliance and administration convenience.

In response to increasing competition, Zoetis continued to emphasize the clinical track record and safety profile of its established dermatology products, including Apoquel and Cytopoint. In February 2026, the company noted a slight moderation in growth due to new market entrants, while maintaining strong global demand supported by its expanded product formats such as chewable therapies.

Recent trends focus on multimodal therapy, extended-duration formulations, and supportive care integration, positioning the market for continued growth in comprehensive, patient-centered management of canine atopic dermatitis.

Key Takeaways

• In 2025, the market generated a revenue of US$ 5.7 Billion, with a CAGR of 11.1%, and is expected to reach US$ 16.3 Billion by the year 2035.
• The product segment is divided into glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies (mAbs) and others, with glucocorticoids taking the lead with a market share of 39.6%.
• Considering type, the market is divided into prescription and OTC. Among these, retrievers (golden/labrador) held a significant share of 55.1%.
• Furthermore, concerning the dog breed segment, the market is segregated into retrievers, german shepherds, terriers and others. The oral sector stands out as the dominant player, holding the largest revenue share of 72.8% in the market.
• The mode of administration segment is segregated into oral, topical and injectable, with the veterinary hospitals/clinics segment leading the market, holding a revenue share of 54.6%.
• North America led the market by securing a market share of 41.2%.

Product Analysis

Glucocorticoids accounted for 39.6% of growth within product and dominate the canine atopic dermatitis market due to their rapid anti-inflammatory action and strong effectiveness in controlling itching and skin irritation. Veterinarians frequently prescribe these drugs for acute flare-ups because they deliver quick relief and improve the dog’s comfort within a short duration.

Clinical observations indicate that allergic skin diseases affect a significant share of dogs, with veterinary dermatology associations noting that up to 10–15% of the canine population shows signs of atopic dermatitis. Glucocorticoids are expected to remain widely used because they provide reliable symptom control in both mild and severe cases.

Pet owners often prefer treatments that show visible improvement quickly, which supports repeated demand for these drugs. The segment benefits from easy availability, established dosing protocols, and cost-effectiveness compared to newer biologic therapies.

Veterinarians also integrate glucocorticoids into combination treatment plans, which further strengthens their role in therapy. Increasing awareness of pet dermatological health is projected to support earlier diagnosis and treatment initiation.

The growing pet population globally is likely to expand the number of treated cases each year. As veterinary care becomes more advanced and accessible, glucocorticoids are estimated to maintain their dominant position due to their clinical reliability and immediate therapeutic impact.

Dog Breed Analysis

Retrievers accounted for 55.1% of growth within dog breed and dominate the canine atopic dermatitis market due to their genetic predisposition to allergic skin conditions and their widespread popularity as companion animals. Veterinary dermatology studies frequently identify breeds such as Labrador Retrievers and Golden Retrievers among the most commonly affected by atopic dermatitis.

These breeds often develop symptoms at an early age, which increases the need for long-term disease management and repeated veterinary visits. High ownership rates of retrievers across North America and Europe contribute significantly to the overall treatment demand. Retrievers are expected to continue leading this segment as pet adoption trends remain strong for these breeds.

Their dense coat and active outdoor lifestyle increase exposure to environmental allergens, which further raises the incidence of skin conditions. Pet owners are becoming more proactive in seeking veterinary care for chronic itching and skin irritation, which supports consistent treatment uptake. The segment is projected to grow as awareness of breed-specific health risks improves among pet owners.

Veterinary professionals also emphasize preventive care and early intervention for high-risk breeds, which increases prescription volumes. As retrievers continue to represent a large share of the global dog population, this segment is anticipated to remain dominant in the canine atopic dermatitis market.

Mode of Administration Analysis

Oral administration accounted for 72.8% of growth within mode of administration and dominates the canine atopic dermatitis market due to its convenience, ease of dosing, and strong compliance among pet owners. Oral medications allow simple administration at home, which reduces the need for frequent veterinary visits and improves adherence to long-term treatment plans.

Veterinarians commonly prescribe oral therapies such as corticosteroids, antihistamines, and immunomodulators because they provide systemic relief from allergic symptoms. Pet owners prefer oral treatments as they fit easily into daily routines and reduce stress for both the animal and caregiver.

The segment is expected to grow further as pharmaceutical companies develop more palatable formulations that improve acceptance among dogs. Oral therapies also support consistent dosing over extended periods, which is essential for managing chronic dermatological conditions.

The segment benefits from wide availability across veterinary clinics and pharmacies, which enhances accessibility. Increasing focus on home-based pet care is likely to reinforce preference for oral medications. As pet owners seek practical and effective solutions for managing recurring skin conditions, oral administration is projected to remain the leading mode in this market.

Distribution Channel Analysis

Veterinary hospitals and clinics accounted for 54.6% of growth within distribution channel and dominate the canine atopic dermatitis market due to their role in diagnosis, prescription, and ongoing disease management. Pet owners rely on veterinarians to accurately identify atopic dermatitis and differentiate it from other skin conditions such as infections or parasitic infestations.

These facilities provide access to specialized dermatological expertise, diagnostic tools, and tailored treatment plans. Veterinary clinics are expected to remain the primary distribution channel as most prescription medications require professional consultation and monitoring. The segment benefits from increasing pet healthcare spending and rising awareness of animal welfare.

Clinics also offer follow-up visits, which support long-term management of chronic conditions and repeat medication purchases. Veterinary professionals often recommend specific treatment regimens and trusted brands, which influences purchasing decisions.

The segment is projected to grow as pet ownership rises globally and veterinary infrastructure expands in developing regions. As pet owners continue to prioritize professional care for their animals, veterinary hospitals and clinics are anticipated to maintain their dominant position in this market.

Key Market Segments

By Product

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• Monoclonal Antibodies (mAbs)
• Others

By Type

• Prescription
• OTC

By Dog Breed

• Retrievers
• German Shepherds
• Terriers
• Others

By Mode of Administration

• Oral
• Topical
• Injectable

Drivers

Increasing revenue from dermatology products for canine atopic dermatitis is driving the market.

Zoetis Inc. reported key dermatology franchise revenue of $1,412 million in fiscal year 2023. This advanced to $1,640 million in fiscal year 2024, representing 17 percent operational growth. In fiscal year 2025, the franchise reached $1,743 million, achieving an additional 6 percent operational increase. The progression demonstrates sustained demand for targeted therapies addressing pruritus and skin inflammation in affected dogs.

Veterinary practices increasingly prescribe these products as part of long-term management protocols for chronic cases. The revenue expansion supports ongoing clinical research into combination therapies and new indications. Owners report improved quality of life metrics following consistent treatment adherence.

The data underscore the role of effective anti-pruritic options in reducing secondary infections and steroid dependency. Facilities achieve better patient compliance through convenient dosing formulations. This driver propels continued investment in dermatology pipelines tailored to canine atopic dermatitis.

Restraints

Moderating growth rates in established dermatology franchises is restraining the market.

Zoetis Inc. documented key dermatology franchise operational growth of 17 percent in fiscal year 2024 compared with 2023. The rate decelerated to 6 percent in fiscal year 2025. This slowdown occurs amid entry of additional therapeutic options and heightened competition within the pruritus control segment.

Practices navigate more selective prescribing amid expanded choice for veterinarians and owners. The restraint pressures pricing dynamics and promotional investments for legacy brands. Manufacturers adjust forecasts to align with tempered volume expectations in mature markets.

The pattern influences allocation of R&D resources toward differentiation rather than broad expansion. Providers encounter challenges maintaining market share without novel mechanisms or delivery innovations. This dynamic moderates overall category momentum during the 2024-2025 transition. The limitation continues to shape strategic planning across the sector.

Opportunities

Approval of novel monoclonal antibodies for pruritus control is creating growth opportunities.

Elanco Animal Health received USDA approval for Befrena, an anti-IL-31 monoclonal antibody injection, during 2025 for management of canine allergic and atopic dermatitis. The product offers a 6- to 8-week dosing interval following initial treatment. Opportunities emerge for extended-interval therapies that improve owner compliance and reduce clinic visits.

The framework supports integration into multimodal protocols combining injectables with oral options. Developers can pursue additional claims through targeted clinical programs. The approval enables differentiation through sustained pruritus relief without daily administration.

Veterinary specialists gain tools for refractory cases previously limited by shorter-acting agents. The opportunity fosters partnerships with diagnostic laboratories for biomarker-guided patient selection. Stakeholders anticipate expanded reimbursement pathways as real-world evidence accumulates. This advancement positions participants for scalable innovation in long-acting biologic treatments.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic conditions and geopolitical dynamics are shaping spending behavior and supply continuity in the canine atopic dermatitis market. Rising disposable income in urban households supports higher pet healthcare expenditure, while inflation pressures reduce discretionary spending for long-term dermatology treatments in some regions.

Veterinary care demand remains steady as pet humanization trends strengthen, yet economic uncertainty leads owners to prioritize essential therapies over premium options. Trade tensions and global logistics disruptions affect the availability of active ingredients and biologics used in dermatology treatments.

Current US tariffs on selected pharmaceutical inputs and medical supplies increase procurement costs for manufacturers and clinics, which leads to pricing adjustments across treatment options. At the same time, these tariffs encourage domestic production and regional supply chain diversification, improving long-term stability.

Veterinary service providers continue to invest in advanced therapies and diagnostics to address chronic skin conditions in pets. Overall, despite pricing and supply challenges, strong pet ownership trends and innovation in treatment approaches are expected to sustain market growth.

Latest Trends

USDA approval of Befrena monoclonal antibody for canine atopic dermatitis is driving the market.

Elanco Animal Health secured USDA approval for Befrena during 2025 as a new anti-IL-31 monoclonal antibody specifically indicated for allergic and atopic dermatitis in dogs. The product delivers targeted pruritus control with an extended 6- to 8-week dosing interval after initial administration. The 2025 milestone introduces a long-acting injectable option for chronic management.

Clinicians benefit from reduced treatment frequency while maintaining efficacy in pruritus and inflammation control. The approval aligns with demands for convenient biologic therapies in dermatology practice. Facilities integrate the product into protocols for moderate-to-severe cases requiring sustained relief.

The development stimulates educational programs on monoclonal antibody applications in allergic skin disease. Early post-approval data demonstrate favorable safety and owner satisfaction profiles. The innovation accelerates adoption of advanced injectables beyond traditional oral agents. Overall, this regulatory advancement elevates therapeutic standards for long-term pruritus management in canine patients.

Regional Analysis

North America is leading the Canine Atopic Dermatitis Market

North America accounted for 41.2% of the canine atopic dermatitis market in 2025 as veterinary dermatology services expanded alongside rising pet ownership and increasing awareness of chronic skin conditions in dogs. Veterinary clinics across the United States and Canada are diagnosing allergic skin diseases more frequently due to improved screening and routine wellness visits.

According to the American Pet Products Association, about 65.1 million U.S. households owned a dog in 2023, creating a large population of companion animals that require ongoing dermatological care. Veterinarians are increasingly prescribing targeted therapies such as monoclonal antibodies, immunomodulators, and advanced topical treatments to manage chronic itching and inflammation.

Growth in specialty veterinary dermatology clinics has improved access to accurate diagnosis and long-term disease management. Pet owners are also showing greater willingness to invest in advanced treatments that improve quality of life for animals with persistent skin conditions.

Pharmaceutical companies are introducing innovative therapies that offer longer duration of action and improved safety profiles. Veterinary education programs are strengthening training in dermatology and allergy management, supporting clinical adoption of advanced treatments. These developments collectively supported steady expansion of dermatological treatment solutions across North America in 2025.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to experience strong growth during the forecast period as pet ownership increases and veterinary care infrastructure improves across the region. Countries such as China, India, Japan, and South Korea are witnessing rapid growth in companion animal populations, particularly among urban households.

The Food and Agriculture Organization reported that the global pet population continues to rise steadily, with significant growth observed in Asia due to urbanization and changing lifestyles. Veterinary clinics across the region are expanding services to include dermatology and allergy management for companion animals.

Pet owners are becoming more aware of chronic skin conditions and are seeking professional treatment rather than relying on basic care. Governments and veterinary associations are strengthening animal healthcare systems and promoting preventive care practices.

Pharmaceutical companies are expanding availability of dermatology treatments tailored to regional markets. Veterinary training institutions are also improving education in companion animal dermatology and allergy management.

Increasing disposable income and demand for premium pet care services are further encouraging treatment adoption. These developments are expected to accelerate growth of dermatological care solutions for companion animals across Asia Pacific in the coming years.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Players Analysis

Key participants in the Canine Atopic Dermatitis market drive growth by advancing targeted therapies, expanding biologic treatments, and strengthening collaborations with veterinary clinics to improve long-term disease management. Companies invest in innovative drug classes such as JAK inhibitors and monoclonal antibodies that deliver rapid itch relief and reduce inflammation in dogs suffering from allergic skin conditions.

They also focus on developing combination treatment approaches, including immunotherapy and supportive care products, to address chronic and recurring symptoms effectively. Zoetis Inc. represents a leading participant in the Canine Atopic Dermatitis market and operates as a global animal health company headquartered in the United States that develops veterinary medicines, vaccines, and biologics for companion animals and livestock.

The company offers therapies such as Apoquel and Cytopoint, which target itch pathways and provide sustained symptom control in dogs. Industry competitors continue to invest in next-generation dermatology drugs, expand veterinary partnerships, and pursue regulatory approvals to strengthen treatment adoption and improve clinical outcomes in canine dermatology.

Top Key Players

• Zoetis Services LLC
• Merck & Co., Inc.
• Elanco
• Boehringer Ingelheim International GmbH
• Virbac
• Dechra
• Biofelix Pharma Group
• Bioiberica S.A.U.
• Ceva

Recent Developments

• In late 2025 and early 2026, Elanco introduced two new therapies targeting companion animal dermatology. These include Zenrelia, an oral JAK inhibitor designed for once-daily dosing, and Befrena, a monoclonal antibody developed for longer-duration treatment. Befrena is positioned to offer extended dosing intervals, supporting more convenient management of chronic dermatological conditions.
• In September 2025, Merck Animal Health presented clinical data on an injectable formulation of fluralaner under the Bravecto brand. The product provides extended protection against fleas for up to one year, offering a long-acting option for managing flea allergy dermatitis, a common contributor to skin-related conditions in companion animals.

Report Scope